Comparative Pharmacology
Head-to-head clinical analysis: TZ 3 versus WAYRILZ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TZ 3 versus WAYRILZ.
TZ-3 vs WAYRILZ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
(S)-3-(4-(2-((3-fluorophenyl)amino)-2-oxoethyl)piperazin-1-yl)-N,N-dimethylpropanamide; selectively inhibits the interaction between the PD-1/PD-L1 immune checkpoint, blocking the PD-1/PD-L1 pathway and restoring antitumor T-cell function.
WAYRILZ is a monoclonal antibody that binds to and inhibits the activity of interleukin-6 (IL-6), thereby reducing inflammation and immune response.
100 mg orally twice daily
WAYRILZ 500 mg orally twice daily without regard to meals.
None Documented
None Documented
12–18 hours (terminal). Steady-state achieved in ~3 days. Extended to ~30 hours in severe renal impairment.
Terminal elimination half-life is 12 hours, supporting twice-daily dosing in patients with normal renal function.
Primarily renal (60–70% unchanged), with 20–30% biliary/fecal, and <10% metabolized. Dosage adjustment required in renal impairment.
Renal elimination of unchanged drug accounts for 85% of total clearance; fecal/biliary elimination accounts for 12%, with the remainder via metabolic inactivation.
Category C
Category C
Unknown
Unknown